Biotinylated Human HLA-B*07:02&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein

Cat. No. MHC-HM469B

Description

Source	Recombinant Biotinylated Human HLA-B*07:02&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus.
	It contains Gly25-Val309(HLA-B*07:02), Ile21-Met119(B2M) and GADGVGKSAL peptide.
Accession	P01889(HLA-B*07:02)&P61769(B2M)&GADGVGKSAL
Molecular Weight	The protein has a predicted MW of 50.40 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	>95% as determined by Bis-Tris PAGE
	>95% as determined by HPLC

Formulation and Storage

Formulation	Supplied as 0.22 μm filtered solution in 20mM PB, 450mM NaCl (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Assay Data

Bis-Tris PAGE



Biotinylated Human HLA-B*07:02&B2M&KRAS G12D (GADGVGKSAL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC



The purity of Biotinylated Human HLA-B*07:02&B2M&KRAS G12D (GADGVGKSAL) Monomer is greater than 95% as determined by SEC-HPLC.